Long-term treatment patterns of testosterone replacement medications - PubMed (original) (raw)
doi: 10.1111/jsm.12608. Epub 2014 Jun 9.
Affiliations
- PMID: 24909541
- DOI: 10.1111/jsm.12608
Long-term treatment patterns of testosterone replacement medications
Craig Donatucci et al. J Sex Med. 2014 Aug.
Abstract
Introduction: Testosterone replacement therapy (TRT) is prescribed to men diagnosed with hypogonadism to alleviate symptoms, improve quality of life, and improve overall health. However, most men use TRT for only a short duration.
Aim: To evaluate the long-term treatment patterns in hypogonadal men using topical TRT or short-lasting TRT injections.
Methods: Using the Truven MarketScan(®) Database, 15,435 men who received their first (index) topical TRT prescription and 517 men who received their short-lasting TRT injection index prescription in 2009 were followed from 12 to 30 months after treatment initiation. Treatment interruption was defined as a medication gap of >30 days. Patients who remained off treatment were classified as having discontinued treatment. Patients who restarted therapy after 30 days were classified as cyclic users. Patients were required to have continuous insurance coverage during 1 year prior to treatment initiation and at least 1 year afterward.
Main outcome measures: Main outcome measures were length of therapy, discontinuation, and restarts of topical TRT or short-lasting TRT injections.
Results: The patient characteristics were similar for patients who received topical TRT or short-lasting TRT injections. Of the patients who discontinued therapy during the follow-up period, the percentages of patients who were still on therapy after 3 months were 52% and 31% for topical TRT and short-lasting TRT users, respectively. For cyclic users, there was an attrition rate of approximately 40% to 50% of patients in each cycle. For both topical TRT and short-lasting TRT injections, the gap between stopping and restarting therapy tended to decrease over time.
Conclusions: In this analysis, high discontinuation rates were observed. The treatment pattern of TRT may be related to the disease state rather than dosing, daily use, or mode of administration.
Keywords: Hypogonadism; Intermittent Medication; Testosterone; Utilization Patterns.
© 2014 International Society for Sexual Medicine.
Similar articles
- Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Schoenfeld MJ, et al. J Sex Med. 2013 May;10(5):1401-9. doi: 10.1111/jsm.12114. Epub 2013 Mar 6. J Sex Med. 2013. PMID: 23464534 - Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A, Almehmadi Y, Saad F, Doros G, Gooren L. Yassin A, et al. Clin Endocrinol (Oxf). 2016 Jan;84(1):107-14. doi: 10.1111/cen.12936. Epub 2015 Oct 2. Clin Endocrinol (Oxf). 2016. PMID: 26331709 - The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
Dinsmore WW, Wyllie MG. Dinsmore WW, et al. BJU Int. 2012 Jul;110(2):162-9. doi: 10.1111/j.1464-410X.2011.10837.x. Epub 2012 Jan 31. BJU Int. 2012. PMID: 22288877 Review. - Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations.
Giagulli VA, Triggiani V, Corona G, Carbone D, Licchelli B, Tafaro E, Resta F, Sabbà C, Maggi M, Guastamacchia E. Giagulli VA, et al. Curr Pharm Des. 2011;17(15):1500-11. doi: 10.2174/138161211796197160. Curr Pharm Des. 2011. PMID: 21521164 Review.
Cited by
- Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations.
Bhat SZ, Dobs AS. Bhat SZ, et al. touchREV Endocrinol. 2022 Nov;18(2):133-140. doi: 10.17925/EE.2022.18.2.133. Epub 2022 Aug 24. touchREV Endocrinol. 2022. PMID: 36694887 Free PMC article. Review. - Testosterone deficiency, insulin-resistant obesity and cognitive function.
Pintana H, Chattipakorn N, Chattipakorn S. Pintana H, et al. Metab Brain Dis. 2015 Aug;30(4):853-76. doi: 10.1007/s11011-015-9655-3. Epub 2015 Feb 24. Metab Brain Dis. 2015. PMID: 25703239 Review. - Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis.
Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF. Borst SE, et al. BMC Med. 2014 Nov 27;12:211. doi: 10.1186/s12916-014-0211-5. BMC Med. 2014. PMID: 25428524 Free PMC article. Review. - The Illusory Case for Treatment of an Invented Disease.
Handelsman DJ. Handelsman DJ. Front Endocrinol (Lausanne). 2022 Jan 18;12:682620. doi: 10.3389/fendo.2021.682620. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35116001 Free PMC article. Review. No abstract available. - Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials.
Guo C, Gu W, Liu M, Peng BO, Yao X, Yang B, Zheng J. Guo C, et al. Exp Ther Med. 2016 Mar;11(3):853-863. doi: 10.3892/etm.2015.2957. Epub 2015 Dec 23. Exp Ther Med. 2016. PMID: 26998003 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous